Avid Bioservices Inc (CDMO)

[InternetForumUser]

Catalysts is something which increase another. I continue to see this list of "CATALYST"; however, none so far has done much for the overall value of the company.

1. Bavi Oncology partnership
Still a possibility but less likely as time passes by
2. Liver cancer IST results. There are interim results to be released at a scientific conference in March.
Not sure what was presented in March could in any way be classified as "Interim Results"
3. Liver cancer partnership
Unlikely at this time
4. Cotara partnership announcement
Only in a dream or someones fantasy
5. Breast cancer IST results
Study Start Date: January 2011 & Estimated Primary Completion Date: December 2013. It is May 2014!!!
6. Breast cancer advancing in clinic
Not sure how this is a catalyst since PPHM has that Breast Trial
7. Ambulance Chaser Lawsuit ended(completely!).
Dismissed and my oh my what a CATALYST it was
8. CSM settlement
Nothing pointing to settlement at this time and according to some Lawyers on this board, it will not mean much
9. Betabodies preclinical
The only type of value this would provide is some adolescent who thinks it is a Bikini Model of some kind
10. Bavi plus other immunotherapies preclinical results...we already have some very interesting Bavi plus Yervoy preclinical results. But there is more to come.In recent presentations PPHM has mentioned 12 or more potential Bavi/immunotherapy combinations. That does not rule out the potential of a cocktail of several of these being used together. So far we have only seen some results from the Bavi/Yervoy preclinical combination. Obviously there is a lot more news to come.
a.anti-CTLA-4 (Yervoy)
b.anti-PD-1
c.anti-PD-L1
d.anti-TGF-b
e.anti-IL-10
f.GM-CSF
g.IFN-a
h.IL-2
i.Provenge
j.other vaccines
k.appropriate TKI
l.radiation plus androgen deprivation
m.anti-CD47 and anti-CD54. Abstract presented at AAI May 2013.
Trial with Yervoy started - Not much ado about nothing.
11. Bavi plus immunotherapy clinical trials. Bavi/Yervoy Phase I could start in January 2014. More could come.
Please read comments from CATALYST #10
12. Dr. Brekken announcements(publications,editorials,presentations). An article appeared in a prestigious EU publication in December. More to come.
Still Waiting.....
13. Another Govt. deal for viruses? HIV presentation in March.
Still Waiting.....
14. Breakthrough, Accelerated Approval or Priority Review announcements?
Still Waiting.....
15. Imaging data update
Still Waiting.....
16. New analyst coverage?
Still Waiting.....
17. Institutional ownership increase?
Some increases but no value to PPS
18. Fast track for second line NSCLC announced in January. AA and PR could follow.
Still Waiting.....
19. Sale of Series E Preferred Convertible shares has now increased the companies cash to some $90 million. More financing news to come...
No need to wait for Financing News when the ATM is available and so easy to use.